MELISSA GABRIELLI: Open Payments
NPI 1548528110 · SAN ANGELO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$711 in 42 payments from 13 companies in 2025. Trend: 2023 $961 · 2024 $546 · 2025 $711
Food & beverage: $711
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $260 |
| Novo Nordisk Inc | 3 | $85 |
| MERZ NORTH AMERICA, INC. | 2 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $61 |
| Axsome Therapeutics, Inc. | 2 | $57 |
| Lilly USA, LLC | 2 | $37 |
| SHIELD THERAPEUTICS INC | 2 | $35 |
| Corium, LLC | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Acella Pharmaceuticals, LLC | 1 | $18 |
Products named: VRAYLAR, QULIPTA, Rybelsus, Xeomin, CAPLYTA, Auvelity, MOUNJARO, ACCRUFER.
Industry payments across TX — which companies pay providers there.
